Mutations in the isocitrate dehydrogenase genes
Gary Kohanbash, Diego A. Carrera, Shruti Shrivastav, Brian J. Ahn, Naznin Jahan, Tali Mazor, Zinal S. Chheda, Kira M. Downey, Payal B. Watchmaker, Casey Beppler, Rolf Warta, Nduka A. Amankulor, Christel Herold-Mende, Joseph F. Costello, Hideho Okada
Treatment with IDH-C35 improves the efficacy of peptide vaccines in mice bearing GL261-MUT tumors.
C57BL/6 mice were vaccinated 3 times with synthetic peptides encoding GAAs presented by GL261 cells (EPHA2671–679, EPHA2682–689, TRP2180–188, GARC1177–185, and HBV core128–140) emulsified in IFA with 20 μg poly-ICLC as an adjuvant. Control mock vaccines consisted of 100 μg HBV core128–140, but without GAA peptides emulsified in IFA with 20 μg Poly-ICLC. Vaccinated mice received intracranial injections of either 1 × 105 GL261-WT or 1 × 105 GL261-MUT cells and received daily treatment with vehicle or 450 mg/kg/day IDH-C35. (